Digbi Health has extended its precision telehealth platform to all 50 states, combining genetic, gut microbiome, blood biomarker and continuous glucose data into individualized metabolic care plans that may include GLP-1 medications or hormone replacement. Peer-reviewed analysis across seven self-insured employers reported a $3,012 annual reduction in medical spend per member. The model positions multi-signal personalization — rather than single-drug prescribing — as the organizing principle of metabolic care at employer scale.
Key Points
- Nationwide telehealth access via 700+ clinicians across 300 employers
- Care plans integrate genetics, microbiome, biomarkers, continuous glucose data
- Published employer data showed $3,012 annual per-member savings
Longevity Analysis
Metabolic dysfunction rarely originates in one place, and treating it through a single pharmacological lever ignores the interplay between gut ecology, glucose handling, hormonal signaling and daily food exposure. Layering continuous glucose data and microbiome profiling underneath prescribing shifts the clinical question from which drug to which interference is driving the signal — and whether medication is addressing the mechanism or masking it. The employer-level cost reduction matters less as a financial figure than as evidence that sustained, data-guided behavioral change can be delivered at population scale, which has historically been the failure point of personalized medicine.
Original published by LT Wire.